Core Viewpoint - The company has received acceptance from the National Medical Products Administration for the marketing authorization application of HR091506 tablets, a novel oral sustained-release formulation of febuxostat [1] Group 1: Product Development - HR091506 tablets are developed using gastric retention formulation technology and feature a pulsatile release characteristic [1] - The product consists of a rapid-release component and a delayed-release component, designed to quickly achieve effective blood drug concentration and maintain it over an extended period [1] Group 2: Market Implications - The sustained-release nature of HR091506 aims to improve the rate of achieving target uric acid levels in patients [1]

Core Viewpoint - The announcement indicates that the subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. of Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of SHR-1894 injection, which is expected to play a role in treating atopic dermatitis by protecting the skin barrier and inhibiting inflammation [1] Group 1: Product Development - SHR-1894 injection is a self-developed therapeutic biological product by the company [1] - The clinical trial for SHR-1894 injection will commence shortly following the approval [1] - The total research and development investment for the SHR-1894 injection project has reached approximately 40.1 million yuan [1] Group 2: Market Context - Currently, there are no similar drugs approved for market release domestically or internationally [1]

Core Viewpoint - The report highlights the current premium rates of AH shares, with Northeast Electric (00042), Zhejiang Shibao (01057), and Sinopec Oilfield Service (01033) leading in premium rates, while CATL (03750), China Merchants Bank (03968), and Hansoh Pharmaceutical (01276) are at the bottom of the list [1]. Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 815.25% - Zhejiang Shibao (01057) with a premium rate of 354.93% - Sinopec Oilfield Service (01033) with a premium rate of 295.40% [1]. - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -11.82% - China Merchants Bank (03968) with a premium rate of -2.30% - Hansoh Pharmaceutical (01276) with a premium rate of 1.62% [1]. Deviation Values - The top three shares with the highest deviation values are: - Goldwind Technology (02208) with a deviation value of 21.73% - Jinyu Group (02009) with a deviation value of 19.04% - Sinopec Oilfield Service (01033) with a deviation value of 18.76% [1]. - The bottom three shares with the lowest deviation values are: - Zhejiang Shibao (01057) with a deviation value of -41.23% - Junda Co., Ltd. (02865) with a deviation value of -39.46% - Yangtze Optical Fibre and Cable (06869) with a deviation value of -26.61% [1]. Additional Insights - The report includes a detailed table of the top and bottom AH shares by premium rate and deviation value, providing a comprehensive overview of the current market situation [2].

Core Viewpoint - Heng Rui Medicine (01276) has seen its stock price increase by over 3%, currently trading at HKD 68.75 with a transaction volume of HKD 71.27 million, following the acceptance of two drug application submissions by the National Medical Products Administration (NMPA) [1][1]. Group 1: Drug Application Acceptance - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received an acceptance notice from the NMPA for the drug application of HR20013, an injectable formulation of Phosphorlorapitant Palonosetron, aimed at preventing nausea and vomiting induced by moderately emetogenic chemotherapy [1][1]. - The application for HR20013 is based on a multicenter, randomized, double-blind, positive-controlled Phase III clinical trial (HR20013-302) evaluating its efficacy and safety [1][1]. Group 2: Innovative Drug Submission - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., also received an acceptance notice from the NMPA for a new indication of the innovative drug, injectable Camrelizumab, in combination with Apatinib Mesylate tablets [1][1]. - This application is based on a randomized controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) comparing the efficacy and safety of Camrelizumab and Apatinib combined with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma [1][1].

每经AI快讯，恒瑞医药(01276.HK)涨超3%，截至发稿，涨3%，报68.75港元，成交额7126.63万港元。 ...

Core Viewpoint - Heng Rui Medicine (600276) has seen its stock price increase by over 3%, currently trading at 68.75 HKD with a transaction volume of 71.27 million HKD, following the acceptance of two drug application submissions by the National Medical Products Administration (NMPA) [1] Group 1: Drug Approvals - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., received an acceptance notice from the NMPA for the marketing authorization application of HR20013, an injectable drug for preventing nausea and vomiting caused by moderately emetogenic anticancer drugs, based on a Phase III clinical trial [1] - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., also received an acceptance notice for the marketing authorization application of a new indication for the innovative drug SHR-1210 (injectable carrelizumab) in combination with apatinib, based on a Phase III clinical trial comparing the efficacy and safety of the combination treatment against TACE alone for patients with unresectable hepatocellular carcinoma [1]

Core Viewpoint - Heng Rui Medicine (01276) has seen its stock price increase by over 3%, currently trading at HKD 68.75, with a transaction volume of HKD 71.27 million [1] Group 1: Regulatory Approvals - The company's subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for the marketing authorization application of HR20013, an injectable drug for preventing nausea and vomiting caused by moderately emetogenic anticancer drugs [1] - The application for HR20013 is based on a multicenter, randomized, double-blind, positive-controlled Phase III clinical trial (HR20013-302) evaluating its efficacy and safety [1] Group 2: New Indications for Existing Drugs - Heng Rui Medicine and its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., have also received a "Notice of Acceptance" from the NMPA for the marketing authorization application of a new indication for the innovative drug, SHR-1210 (injectable carrelizumab) in combination with apatinib mesylate tablets [1] - This application is based on a randomized controlled, open-label, multicenter Phase III clinical trial (SHR-1210-III-336 study) comparing the efficacy and safety of carrelizumab and apatinib combined with TACE versus TACE alone in patients with unresectable hepatocellular carcinoma [1]

智通财经APP讯，恒瑞医药(01276)发布公告，于2026年2月4日，该公司斥资931.7万元回购16.5万股A 股。 ...

Group 1 - The core point of the article is that Heng Rui Medicine (01276.HK) announced a share buyback on February 4, 2026, spending RMB 9.317 million to repurchase 165,000 A-shares at a price range of RMB 56.25 to 57.09 per share [1][1][1] Group 2 - Heng Rui Medicine's share buyback reflects the company's strategy to enhance shareholder value and confidence in its stock performance [1] - The company has also received acceptance for the marketing authorization application of "Injectable Phosphorlorapitant Palonosetron" from Fujian Shengdi Medicine [1]